ATE403657T1 - Chemische verbindungen - Google Patents

Chemische verbindungen

Info

Publication number
ATE403657T1
ATE403657T1 AT02776075T AT02776075T ATE403657T1 AT E403657 T1 ATE403657 T1 AT E403657T1 AT 02776075 T AT02776075 T AT 02776075T AT 02776075 T AT02776075 T AT 02776075T AT E403657 T1 ATE403657 T1 AT E403657T1
Authority
AT
Austria
Prior art keywords
chemical compounds
derivatives
methods
pyrazolo
diseases
Prior art date
Application number
AT02776075T
Other languages
English (en)
Inventor
Jerry Adams
Jiri Kasparec
Domingos Silva
Catherine Yuan
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE403657T1 publication Critical patent/ATE403657T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02776075T 2001-10-02 2002-10-01 Chemische verbindungen ATE403657T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32650601P 2001-10-02 2001-10-02

Publications (1)

Publication Number Publication Date
ATE403657T1 true ATE403657T1 (de) 2008-08-15

Family

ID=23272496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02776075T ATE403657T1 (de) 2001-10-02 2002-10-01 Chemische verbindungen

Country Status (8)

Country Link
US (1) US7217710B2 (de)
EP (1) EP1432714B1 (de)
JP (1) JP4459619B2 (de)
AT (1) ATE403657T1 (de)
AU (1) AU2002341920A1 (de)
DE (1) DE60228103D1 (de)
ES (1) ES2309206T3 (de)
WO (1) WO2003029209A2 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638966B1 (de) * 2003-05-28 2008-03-19 Universita Degli Studi Di Siena 4-substituierte derivate von pyrazolo¬3,4-d pyrimidin und deren verwendungen
JP2007517007A (ja) * 2003-12-24 2007-06-28 アストラゼネカ アクチボラグ Ｔｉｅ２（ＴＥＫ）活性を持つピリミジン
TW200530236A (en) * 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
CA2557575A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
CA2558109A1 (en) * 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
RU2006134022A (ru) 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные индазола и содержащие их фармацевтические композиции
US7405220B2 (en) * 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
ES2368930T3 (es) 2004-09-06 2011-11-23 Bayer Pharma Aktiengesellschaft Pirazolopirimidinas como inhibidores de proteína cinasa b (akt).
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0427604D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
EP1863805A1 (de) * 2005-02-01 2007-12-12 AstraZeneca AB Pyrimidinverbindungen mit tie2- (tek-) hemmender wirkung
US20080146599A1 (en) * 2005-02-01 2008-06-19 Astrazeneca Ab Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity
GB0502418D0 (en) * 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
WO2007023111A2 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
GB0524436D0 (en) * 2005-11-30 2006-01-11 Novartis Ag Organic compounds
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
GB0610242D0 (en) * 2006-05-23 2006-07-05 Novartis Ag Organic compounds
US8008035B2 (en) * 2007-01-25 2011-08-30 Roche Diagnostics Operations, Inc. Enhancement of vanadium-containing phosphatase inhibitors
EP1949894B1 (de) * 2007-01-25 2016-06-29 Roche Diagnostics GmbH Verstärkung von vanadiumhaltigen Phosphatasehemmern mit Polyole
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
BRPI0817101A2 (pt) 2007-09-14 2017-05-09 Addex Pharmaceuticals Sa 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
ES2494365T3 (es) * 2008-01-30 2014-09-15 Genentech, Inc. Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
JP5547099B2 (ja) * 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
US8220787B2 (en) * 2008-09-19 2012-07-17 Panasonic Corporation Part mounting device
SG171765A1 (en) 2008-11-20 2011-07-28 Genentech Inc Pyrazolopyridine pi3k inhibitor compounds and methods of use
ES2401691T3 (es) 2008-11-28 2013-04-23 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
EP2448938B9 (de) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinone als pi3k-hemmer
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
EP2558463A1 (de) 2010-04-14 2013-02-20 Incyte Corporation Kondensierte derivate als i3-hemmer
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US8362023B2 (en) * 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102030609B1 (ko) 2011-09-02 2019-10-11 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AU2011376717A1 (en) 2011-09-14 2014-03-20 Proximagen Limited New enzyme inhibitor compounds
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
WO2013052417A1 (en) 2011-10-03 2013-04-11 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
RU2014145121A (ru) 2012-05-22 2016-07-10 Зэ Юниверсити Оф Норд Каролина Эт Чапел Хилл Пиримидиновые соединения для лечения злокачественной опухоли
EP2909211A4 (de) 2012-10-17 2016-06-22 Univ North Carolina Pyrazolopyrimidinverbindungen zur krebsbehandlung
EP2925752A4 (de) 2012-11-27 2016-06-01 Univ North Carolina Pyrimidinverbindungen zur krebsbehandlung
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
WO2015157122A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrazolopyrimidine compounds
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
ES2747249T3 (es) 2014-07-17 2020-03-10 Sunshine Lake Pharma Co Ltd Derivados de 1-(5-(terc-butil)isoxazol-3-il)-3-(4-((fenil)etinil)fenil)urea y compuestos relacionados como inhibidores de FLT3 para el tratamiento de cáncer
DK3831833T3 (da) 2015-02-27 2022-11-14 Incyte Holdings Corp Fremgangsmåder til fremstillingen af en pi3k-inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
GB201801562D0 (en) 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
CN119258070A (zh) 2018-06-01 2025-01-07 因赛特公司 治疗pi3k相关病症的给药方案
WO2019236631A1 (en) * 2018-06-05 2019-12-12 Rapt Therapeutics, Inc. Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
WO2020115501A1 (en) 2018-12-06 2020-06-11 Almac Discovery Limited Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU711592B2 (en) * 1995-04-03 1999-10-14 Novartis Ag Pyrazole derivatives and processes for the preparation thereof
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
WO1998014449A1 (en) 1996-10-02 1998-04-09 Novartis Ag Fused pyrazole derivatives and processes for their preparation
IL148718A0 (en) * 1999-09-17 2002-09-12 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents

Also Published As

Publication number Publication date
EP1432714A2 (de) 2004-06-30
US20040198751A1 (en) 2004-10-07
US7217710B2 (en) 2007-05-15
ES2309206T3 (es) 2008-12-16
WO2003029209A2 (en) 2003-04-10
JP2005504828A (ja) 2005-02-17
WO2003029209A3 (en) 2004-02-12
EP1432714A4 (de) 2005-10-19
AU2002341920A1 (en) 2003-04-14
DE60228103D1 (de) 2008-09-18
EP1432714B1 (de) 2008-08-06
JP4459619B2 (ja) 2010-04-28

Similar Documents

Publication Publication Date Title
ATE403657T1 (de) Chemische verbindungen
NO2022001I1 (no) Pazopanib
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
DE60314623D1 (de) Substituierte pyrazolopyrimidine
EA200700225A1 (ru) Аналоги тетрапептида
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
SE0301700D0 (sv) Novel compounds
DE60107687D1 (de) Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden
CY1106032T1 (el) Υποκατασταθεισες πυραζολες
WO2003051886A8 (en) Pyrazolopyridazine derivatives
WO2004032882A3 (en) Chemical compounds
WO2003072541A3 (en) Chemical compounds
WO2004069160A3 (en) Chemical compounds
SE0102716D0 (sv) Novel compounds
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE60228295D1 (de) Chemische verbindungen
ATE281455T1 (de) Oxindolderivate
NO20053562L (no) Nye aminobenzofenonforbindelser
ATE339420T1 (de) Neue verbindungen
DE60110468D1 (de) Chemische verbindungen
ATE344666T1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties